comparemela.com

Latest Breaking News On - Hr breast cancer - Page 2 : comparemela.com

Testing for ESR1 Mutations in Breast Cancer

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Erical mayerKevin kalinskyBreast cancerHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsBiomarker testingEsr1 testingAsco recommendationsCirculating tumor dna

Overcoming Challenges in Biomarker Testing in Breast Cancer

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

Breast cancerBiomarker testingHr breast cancerHr positive breast cancerBreast cancer treatmentEsr1 mutationsEsr1 testingAsco recommendationsCirculating tumor dna

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Aromatase inhibitor resistant hormoneHuman epidermal growth factor receptorAdvanced breast cancerBreast cancerHr breast cancerHer2 breast cancerCapitello trialCapitello 291Jcdk4 6 inhibitorPik3ca alterationAkt1 alterationPten alterationCapivasertib adverse eventsAdverse eventsFulvestrant capivasertibFulvestrant adverse events

COMING SOON: Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

Expert oncologist Aditya Bardia, MD, shares his excitement for an upcoming program centered on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Datopotamab deruxtecanPrimary resultsRandomized phaseBreast cancerMetastatic breast cancerHr breast cancerHer2 breast cancerDato dxdNovel therapyClinical trialEsmo 2023Esmo congress

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Optimizing treatmentMultidisciplinary approachBreast cancerHr breast cancerHer2 breast cancerHr her2 breast cancerHer2 negative breast cancerHr positive breast cancerBreast cancer treatmentsBreast cancer therapiesMultidisciplinary careMedical oncologistsRadiation oncologists

vimarsana © 2020. All Rights Reserved.